Get the Weekly Intelligence Brief — top committee picks every Sunday.

ACAD vs SYRE

ACADIA Pharmaceuticals Inc. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
MetricACADSYRE
AI Score 69 67
Price $29.41 $102.72
P/E Ratio 13.07× -52.69×
ROE 31.9% -21.7%
Revenue Growth YoY
Gross Margin 91.1% 0.0%
Debt / Equity 0.06× 0.00×
Dividend Yield 0.0% 0.0%
RSI (14) 78.4 53.3
Beta 0.845 3.026
Expected Upside

AI Committee View

Current Innellis committee reasoning for ACAD versus SYRE.
ACAD leads by 2 points.

ACAD scores 69/100 (Buy) versus SYRE at 67/100 (Insufficient Data).

ACAD Committee View
83% agreement
6 analysts

The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.

Bull Case
  • P/E of 13.2 is inexpensive for the broad market — Value
  • ROE of 32.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
  • RSI at 78 is in overbought territory — Technical
  • Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 24.3% signals elevated volatility — Risk
SYRE Committee View
100% agreement
3 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • MACD histogram negative -- bearish momentum — Technical
  • Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ACAD Full Analysis SYRE Full Analysis